Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:DOVA NASDAQ:KNSA NASDAQ:RYTM NASDAQ:ZIOP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.63-4.1%$1.74$1.41▼$5.01$9.40M1.1927,284 shs38,234 shsDOVADova Pharmaceuticals$28.04$28.04$5.62▼$28.54$807.55M2.74499,313 shs35,036 shsKNSAKiniksa Pharmaceuticals International$28.09-2.5%$27.72$17.82▼$30.69$2.10B0.05555,431 shs404,501 shsRYTMRhythm Pharmaceuticals$89.36+0.2%$64.34$40.61▼$94.80$5.69B2.26589,878 shs852,325 shsZIOPZIOPHARM Oncology$1.08$0.77▼$5.95$187.12M1.712.01 million shs2.13 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-1.73%-1.73%-10.05%+7.59%-58.64%DOVADova Pharmaceuticals0.00%0.00%0.00%0.00%0.00%KNSAKiniksa Pharmaceuticals International+2.53%+3.04%+1.77%+35.72%+35.79%RYTMRhythm Pharmaceuticals+2.83%+34.28%+41.73%+43.58%+78.23%ZIOPZIOPHARM Oncology0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.9304 of 5 stars3.53.00.00.02.70.81.3DOVADova PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals International3.561 of 5 stars3.54.00.00.03.03.30.6RYTMRhythm Pharmaceuticals3.1614 of 5 stars2.51.00.04.32.60.80.6ZIOPZIOPHARM OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50850.92% UpsideDOVADova Pharmaceuticals 0.00N/AN/AN/AKNSAKiniksa Pharmaceuticals International 3.00Buy$39.3340.03% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$91.001.84% UpsideZIOPZIOPHARM Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZIOP, APRE, DOVA, RYTM, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/10/2025RYTMRhythm PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$76.00 ➝ $110.007/10/2025RYTMRhythm PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $95.007/10/2025RYTMRhythm PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$91.00 ➝ $129.007/10/2025RYTMRhythm PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$97.007/9/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$95.007/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.007/9/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $95.007/7/2025RYTMRhythm PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025RYTMRhythm PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$88.006/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.01N/AN/A$3.55 per share0.46DOVADova Pharmaceuticals$10.35M78.02N/AN/A$2.71 per share10.35KNSAKiniksa Pharmaceuticals International$423.24M4.84N/AN/A$6.60 per share4.26RYTMRhythm Pharmaceuticals$130.13M43.69N/AN/A$0.35 per share255.31ZIOPZIOPHARM OncologyN/AN/AN/AN/A$0.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.370.00N/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)DOVADova Pharmaceuticals-$72.28M-$2.60N/AN/AN/A-544.09%-101.60%-67.21%N/AKNSAKiniksa Pharmaceuticals International-$43.19M-$0.250.00112.36N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)ZIOPZIOPHARM Oncology-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/ALatest ZIOP, APRE, DOVA, RYTM, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025APREAprea Therapeutics-$0.77N/AN/AN/AN/AN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.64N/AN/AN/A$43.72 millionN/A7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ADOVADova PharmaceuticalsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.905.90DOVADova Pharmaceuticals0.415.645.37KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43RYTMRhythm PharmaceuticalsN/A3.303.13ZIOPZIOPHARM Oncology0.183.433.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%DOVADova Pharmaceuticals33.03%KNSAKiniksa Pharmaceuticals International53.95%RYTMRhythm PharmaceuticalsN/AZIOPZIOPHARM Oncology51.03%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%DOVADova Pharmaceuticals60.30%KNSAKiniksa Pharmaceuticals International53.48%RYTMRhythm Pharmaceuticals6.10%ZIOPZIOPHARM Oncology5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataDOVADova Pharmaceuticals11528.80 millionN/AOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableZIOPZIOPHARM Oncology105216.15 million204.91 millionOptionableZIOP, APRE, DOVA, RYTM, and KNSA HeadlinesRecent News About These CompaniesTCRT stock touches 52-week low at $1.62 amid market challengesJanuary 30, 2025 | msn.comBest Global Universities for OncologySeptember 11, 2024 | usnews.comFDA fast-tracks Merck's cancer blockbuster-in-waitingJuly 28, 2024 | pharmaphorum.comPBMS signs $475m cancer immunotherapy deal with DragonflyJuly 23, 2024 | pharmaphorum.comPChildhood CancersFebruary 17, 2024 | curetoday.comCAlx Oncology Holdings (ALXO)February 10, 2024 | investing.comPediatric Hematology-Oncology FellowshipFebruary 5, 2024 | bcm.eduBAlaunos Therapeutics: Other Events, Financial Statements And ExhibitsJanuary 31, 2024 | cbonds.comCCG Oncology IncJanuary 31, 2024 | reuters.comOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsDecember 21, 2023 | medscape.comMImmuno-OncologyDecember 19, 2023 | ajmc.comAWhy Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?December 18, 2023 | markets.businessinsider.comExploring Patient-Centered Handoffs in Surgical OncologyDecember 10, 2023 | medscape.comMAssociation of Community Cancer CentersOctober 14, 2023 | ajmc.comAOncology News and ResearchSeptember 19, 2023 | news-medical.netNWBSPH 2024 - OncologySeptember 15, 2023 | newsweek.comNKris on OncologySeptember 6, 2023 | medscape.comMGauging Ziopharm's Chances for Positive Sarcoma Drug Trial ResultsAugust 29, 2023 | thestreet.comOncology Cases & QuizzesAugust 14, 2023 | medscape.comMZiopharm’s palifosfamide fails in first-line STS…June 20, 2023 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZIOP, APRE, DOVA, RYTM, and KNSA Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.64 -0.06 (-3.53%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Dova Pharmaceuticals NASDAQ:DOVADova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.Kiniksa Pharmaceuticals International NASDAQ:KNSA$28.09 -0.71 (-2.47%) Closing price 04:00 PM EasternExtended Trading$28.30 +0.21 (+0.75%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Rhythm Pharmaceuticals NASDAQ:RYTM$89.36 +0.21 (+0.24%) Closing price 04:00 PM EasternExtended Trading$88.94 -0.42 (-0.47%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.ZIOPHARM Oncology NASDAQ:ZIOPZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.